Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis.
INTRODUCTION
Ankylosing spondylitis is the prototype of spondyloarthritis, a chronic inflammatory disease involving mainly the axial skeleton. The treatment strategy was, until now, restricted to NSAIDs and anti-TNF agents. Targeting Interleukin 17 is an emerging option with a currently available biologic agent, secukinumab.


AREAS COVERED
This paper reviews the available data published on secukinumab (and other anti-IL-17 agents) in ankylosing spondylitis, evaluating the effect on clinical outcomes as well as radiological progression and extra articular manifestations and safety.


EXPERT OPINION
Secukinumab represents the first anti-IL-17A agent available for the treatment of ankylosing spondylitis, with evidence of efficacy upon signs and symptoms of the disease, even after anti-TNF failure, and acceptable safety profile.
['Wendling|Daniel|D|', 'Verhoeven|Frank|F|', 'Prati|Clément|C|']
D000911:Antibodies, Monoclonal D061067:Antibodies, Monoclonal, Humanized D002986:Clinical Trials as Topic D003362:Cost-Benefit Analysis D006801:Humans D020381:Interleukin-17 D013167:Spondylitis, Ankylosing D058504:Th17 Cells
Ankylosing spondylitis spondyloarthritis Interleukin 17 secukinumab ixekizumab